NCT01540864

A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects

A 26 Week Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of Various Doses of HPP404 on Weight Loss in Overweight or Obese Subjects

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 126 (actual)
• Sponsor: High Point Pharmaceuticals, LLC. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the safety and effect of HPP404 versus placebo on body weight in overweight or obese subjects.

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	HPP404	Administered orally once daily for 26 weeks
DRUG	Placebo	Administered orally once daily for 26 weeks

Timeline

• Start date: 2012-05-01
• Primary completion: 2013-05-01
• Completion: 2013-05-01
• First posted: 2012-02-29
• Last updated: 2015-09-04

Locations

10 sites across 1 country: United States